Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PLATPARP trial (niraparib): what clinicians have said so far
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
- NCT04288687 ↗
- Completed
- Abramson Cancer Center at Penn Medicine
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on PLATPARP (niraparib in platinum-sensitive castration-resistant prostate cancer with DNA repair defects) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PLATPARP so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- PLATPARP: A Phase II Single-Arm Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Niraparib Pill
- Arms
- Niraparib Arm (only arm) · Other
- Enrollment
- 11
- Primary outcomes
- 6-Month Radiographic Progression-Free Survival (rPFS6)
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Start
- Oct 19, 2020
- Primary completion
- Feb 20, 2024
- Results posted
- Yes
- Registry record
- NCT04288687 · updated Mar 4, 2026